SkinBioTherapeutics - Appointment of Joint Broker

SkinBioTherapeutics plc

Appointment of Joint Broker

Manchester, UK - 5 January 2018 - SkinBioTherapeutics plc (AIM: SBTX,  the "Company"), a life science company focused on skin health, announces the appointment of Northland Capital Partners to act as the Company's Joint Corporate Broker, alongside Turner Pope Investments, with immediate effect.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

-Ends-

For more information, please contact:

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin.  The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models.  Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017 concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.